Description
Larazotide (specifically larazotide acetate) is an investigational, orally administered synthetic peptide being studied as an adjunct therapy for celiac disease and Long COVID. It works by regulating tight junctions in the gut lining to reduce intestinal permeability—often referred to as a “leaky gut”.
How It Works
- Zonulin Antagonist: Larazotide blocks the zonulin receptor on the surface of intestinal cells.
- Tight Junction Regulation: By blocking this receptor, it prevents the widening of the gaps (tight junctions) between cells in the gut wall.
- Barrier Protection: This tightening restricts harmful substances (such as gluten fragments or viral antigens) from leaking through the gut barrier and triggering inflammation.
Primary Conditions Studied
- Celiac Disease: It has been heavily researched as a complementary treatment alongside a gluten-free diet to help prevent gastrointestinal symptoms when accidental gluten exposure occurs.
- Long COVID: Recent clinical trials are exploring larazotide as a way to reduce systemic inflammation by preventing viral particles from escaping the gut into the bloodstream in patients with Long COVID
Reviews
There are no reviews yet.